VivoSeq
Metabolic & Endocrine

Primary Adrenal Insufficiency

6

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Primary Adrenal Insufficiency is an early-stage landscape with 6 programs across 3 companies. The most active players are Inflabloc Pharmaceuticals, Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Quince Therapeutics S.p.A.. 4 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Inflabloc Pharmaceuticals

1 program

Phase 3P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

2 programs

ApprovedQ

Quince Therapeutics S.p.A.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

1

clinical trials

Completed1 · 100%

Clinical Trials

Trial Activity

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency
Completed·NNational Center for Research Resources (NCRR)·Phase 3·NCT00004313·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)